or on the link below. Patients received escalating intravenous obrixtamig doses using four regimens: a fixed dose once every 3 weeks (A); a fixed dose once weekly (B1); a step-up dose once weekly for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer ...
The MarketWatch News Department was not involved in the creation of this content. -- Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical ...
Tarlatamab-dlle significantly improves overall survival in SCLC compared to standard chemotherapy, as demonstrated in the phase 3 DeLLphi-304 trial. The bispecific T-cell engager targets DLL3 on tumor ...
Initial study to focus on small cell lung cancer (SCLC), with potential extension into other tumor types such as neuroendocrine tumors (NET) SHANGHAI & HONG KONG, June 29, 2026--(BUSINESS ...
Please provide your email address to receive an email when new articles are posted on . MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, ...
Add Yahoo as a preferred source to see more of our stories on Google. Obrixtamig is an investigational bispecific DLL3 engager that targets DLL3-expressing cancer cells in SCLC and NECs. Credit: CI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results